Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

MCL Survival Rates Improve With Novel Agents

Key clinical point: Survival rates for patients with mantle cell lymphoma (MCL) improved from 1995 to 2013 with the introduction of new treatments.

Major finding: All-cause mortality rates among MCL patients were significantly reduced from 1995 to 2013 in two cancer databases (SEER, P less than .001; TCR, P = .03).

Study details: A retrospective analysis of 9,610 patients with MCL.

Disclosures: The study was supported by grant funding from the Cancer Prevention Research Institute of Texas and the National Institutes of Health. The researchers reported having no conflicts of interest.

Citation:

Fu S et al. Cancer Epidemiol. 2019 Feb:58:89-97.